171 related articles for article (PubMed ID: 27870477)
1. Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.
Glue P; Cape G; Tunnicliff D; Lockhart M; Lam F; Hung N; Hung CT; Harland S; Devane J; Crockett RS; Howes J; Darpo B; Zhou M; Weis H; Friedhoff L
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):460-468. PubMed ID: 27870477
[TBL] [Abstract][Full Text] [Related]
2. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.
Glue P; Lockhart M; Lam F; Hung N; Hung CT; Friedhoff L
J Clin Pharmacol; 2015 Feb; 55(2):189-94. PubMed ID: 25279818
[TBL] [Abstract][Full Text] [Related]
3. Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.
Glue P; Cape G; Tunnicliff D; Lockhart M; Lam F; Gray A; Hung N; Hung CT; Harland S; Devane J; Howes J; Weis H; Friedhoff L
J Clin Pharmacol; 2016 Aug; 56(8):960-5. PubMed ID: 26763764
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
Knuijver T; Ter Heine R; Schellekens AFA; Heydari P; Lucas L; Westra S; Belgers M; van Oosteren T; Verkes RJ; Kramers C
J Psychopharmacol; 2024 May; 38(5):481-488. PubMed ID: 38519421
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
[TBL] [Abstract][Full Text] [Related]
6. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.
Mash DC; Ameer B; Prou D; Howes JF; Maillet EL
J Psychopharmacol; 2016 Jul; 30(7):688-97. PubMed ID: 27044509
[TBL] [Abstract][Full Text] [Related]
7. How toxic is ibogaine?
Litjens RP; Brunt TM
Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
[TBL] [Abstract][Full Text] [Related]
8. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine.
Henstra M; Wong L; Chahbouni A; Swart N; Allaart C; Sombogaard F
Clin Toxicol (Phila); 2017 Jul; 55(6):600-602. PubMed ID: 28489458
[TBL] [Abstract][Full Text] [Related]
9. Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice.
Bhargava HN; Cao YJ
Brain Res; 1997 Oct; 771(2):343-6. PubMed ID: 9401754
[TBL] [Abstract][Full Text] [Related]
10. Ibogaine-like effects of noribogaine in rats.
Glick SD; Pearl SM; Cai J; Maisonneuve IM
Brain Res; 1996 Mar; 713(1-2):294-7. PubMed ID: 8725004
[TBL] [Abstract][Full Text] [Related]
11. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
Mash DC; Kovera CA; Pablo J; Tyndale RF; Ervin FD; Williams IC; Singleton EG; Mayor M
Ann N Y Acad Sci; 2000 Sep; 914():394-401. PubMed ID: 11085338
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.
Sunder Sharma S; Bhargava HN
Pharmacology; 1998 Nov; 57(5):229-32. PubMed ID: 9742287
[TBL] [Abstract][Full Text] [Related]
13. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
14. Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.
Zubaran C; Shoaib M; Stolerman IP; Pablo J; Mash DC
Neuropsychopharmacology; 1999 Jul; 21(1):119-26. PubMed ID: 10379526
[TBL] [Abstract][Full Text] [Related]
15. Modulation of morphine-induced antinociception by ibogaine and noribogaine.
Bagal AA; Hough LB; Nalwalk JW; Glick SD
Brain Res; 1996 Nov; 741(1-2):258-62. PubMed ID: 9001731
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of antiaddictive actions of ibogaine.
Glick SD; Maisonneuve IS
Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
[TBL] [Abstract][Full Text] [Related]
17. Effects of low dose ibogaine on subjective mood state and psychological performance.
Forsyth B; Machado L; Jowett T; Jakobi H; Garbe K; Winter H; Glue P
J Ethnopharmacol; 2016 Aug; 189():10-3. PubMed ID: 27180314
[TBL] [Abstract][Full Text] [Related]
18. A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats.
Rodrı Guez P; Urbanavicius J; Prieto JP; Fabius S; Reyes AL; Havel V; Sames D; Scorza C; Carrera I
ACS Chem Neurosci; 2020 Jun; 11(11):1661-1672. PubMed ID: 32330007
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
20. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
Brown TK; Alper K
Am J Drug Alcohol Abuse; 2018; 44(1):24-36. PubMed ID: 28541119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
